Frank Derosa

This inventor holds 28 USPTO granted patents and 16 published patent applications, plus 3 CIPO patents and 47 EPO patents, primarily in Messenger RNA Delivery. Top assignees: Translate Bio, Inc., Translate Bio MA, Inc., Ethris Gmbh. Active years: 2025-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Frank Derosa. Retrieved from https://idiyas.com/inventor/frank-derosa-hox1yep0

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 28 (Patent Applications = 16)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 47 (Patent Applications = 122)

Average Co-Inventor Count = 3.8

ph-index = 1

Company Filing History:

Translate Bio MA, Inc.

where one patent can have more than one assignee

Years Active: 2025-2026

Loading Chart...

Areas of Expertise:

Lipid Nanoparticles

Cationic Lipids

mRNA Therapy

RNA Purification

Cystic Fibrosis

Dry Powder Formulations

Blended Formulations

Ionizable Lipids

Codon-Optimized mRNA

Phenolic Acid Lipids

Pulmonary Delivery

Nucleic Acid Delivery

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12758508 - Process of Preparing mRNA-Loaded Lipid Nanoparticles (2026-10-13),

2. 12747198 - Phenolic acid lipid based cationic lipids (2026-09-29),

3. 12746203 - Pumpless encapsulation of messenger RNA (2026-09-29),

4. 12734253 - PROCESSES OF PREPARING MRNA-LOADED LIPID NANOPARTICLES (2026-09-15),

5. 12702693 - TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF CODON-OPTIMIZED mRNA ENCODING CFTR (2026-08-11),

6. 12698258 - Cystine cationic lipids (2026-08-04),

7. 12697309 - MRNA-loaded lipid nanoparticles and processes of making the same (2026-08-04),

8. 12697302 - Tricine and citric acid lipids (2026-08-04),

9. 12697301 - Pulmonary Delivery of MRNA to Non-lung Target Cells (2026-08-04),

10. 12678406 - Process of preparing ice-based lipid nanoparticles (2026-07-14),

11. 12636252 - PROCESS OF PREPARING MRNA-LOADED LIPID NANO PARTICLES (2026-05-26),

12. 12600998 - Large Scale Synthesis of Messenger RNA (2026-04-14),

13. 12594295 - CFTR MRNA COMPOSITIONS AND RELATED METHODS AND USES (2026-04-07),

14. 12594245 - Dry Powder Formulations for Messenger RNA (2026-04-07),

15. 12577600 - MODIFICATION OF RNA-RELATED ENZYMES FOR ENHANCED PRODUCTION (2026-03-17),

Title: Frank Derosa: Innovator in Lipid Delivery Systems

Introduction

Frank Derosa is a prominent inventor based in Lexington, MA (US), known for his significant contributions to the field of lipid delivery systems. With a total of 28 patents, he has developed innovative compounds that enhance the delivery of therapeutic agents to target cells.

Latest Patents

Among his latest patents, Derosa has disclosed novel compounds known as ionizable cationic lipids. These compounds are designed to serve as liposomal delivery vehicles, facilitating the delivery of encapsulated polynucleotides to target cells and enabling their subsequent transfection. The unique properties of these compounds provide advantages over other similarly classified lipids. Another notable patent involves di-thioester cationic lipids, which are useful for the delivery and expression of mRNA and encoded proteins. These compounds can be utilized in liposomal delivery vehicles, offering potential treatments for various diseases associated with protein deficiencies.

Career Highlights

Throughout his career, Frank Derosa has worked with esteemed organizations such as Translate Bio, Inc. and the Massachusetts Institute of Technology. His work has significantly advanced the understanding and application of lipid-based delivery systems in pharmaceuticals.

Collaborations

Derosa has collaborated with notable colleagues, including Michael W Heartlein and Anusha Dias, contributing to the development of innovative solutions in the field of biotechnology.

Conclusion

Frank Derosa's work in lipid delivery systems exemplifies the impact of innovative thinking in the pharmaceutical industry. His patents and collaborations continue to pave the way for advancements in therapeutic delivery methods.

Profile summary based on public USPTO records.